HnRNP K is a heterogeneous nuclear ribonucleoprotein and has been identified as an oncogene in most solid tumors via regulating gene expression or alternative splicing of genes by binding both DNA and pre-mRNA. However, how hnRNP K affects tumorigenesis and regulates the gene expression in cervical cancer (CESC) remains to be elucidated. In these data, higher expression of hnRNP K was observed in CESC and was negatively correlated with the patient survival time. We then overexpressed hnRNP K (hnRNP K-OE) and found that its overexpression promoted cell proliferation in HeLa cells (P = 0.0052). Next, global transcriptome sequencing (RNA-seq) experiments were conducted to explore gene expression and alternative splicing profiles regulated by hnRNP K. It is shown that upregulated genes by hnRNP K-OE were associated with inflammatory response and an apoptotic process of neuron cells, which involves in cancer. In addition, the alternative splicing of those genes regulated by hnRNP K-OE was associated with transcriptional regulation. Analysis of the binding features of dysregulated transcription factors (TFs) in the promoter region of the inflammatory response genes regulated by hnRNP K revealed that hnRNP K may modulate the expression level of genes related to inflammatory response by influencing the alternative splicing of TFs. Among these hnRNP K-TFs-inflammatory gene regulatory networks, quantitative reverse transcription polymerase chain reaction (RT-qPCR) experiments and gene silencing were conducted to verify the hnRNP K-IRF1-CCL5 axis. In conclusion, the hnRNP K-TFs-inflammatory gene regulatory axis provides a novel molecular mechanism for hnRNP K in promoting CESC and offers a new therapeutic target.
JemalABrayFCenterMMFerlayJWardEFormanD.Global cancer statistics.CA: Cancer J Clin2011;61:69–90
2.
SankaranarayananREsmyPORajkumarRMuwongeRSwaminathanRShanthakumariSFayetteJ-MCherianJ.Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial.Lancet2007;370:398–406
3.
SankaranarayananR.HPV vaccination: the promise & problems.Indian J Med Res2009;130:322–6
4.
RoncoGGiorgi-RossiPCarozziFConfortiniMDalla PalmaPDel MistroAGhiringhelloBGirlandoSGillio-TosADe MarcoLNaldoniCPierottiPRizzoloRSchincagliaPZorziMZappaMSegnanNCuzickJ, New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.Lancet Oncol2010;11:249–57
5.
RoncoGDillnerJElfstromKMTunesiSSnijdersPJArbynMKitchenerHSegnanNGilhamCGiorgi-RossiPBerkhofJPetoJMeijerCJ.Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.Lancet (London, England)2014;383:524–32
6.
AngioliRPlottiFLuveroDAloisiAGuzzoFCapriglioneSTerranovaCDe Cicco NardoneCBenedetti-PaniciP.Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study.Tumour Biol2014;35:2741–6
7.
Organista-NavaJGomez-GomezYGariglioP.Embryonic stem cell-specific signature in cervical cancer.Tumour Biol2014;35:1727–38
8.
FangMKanYDongDYuTZhaoNJiangWZhongLHuCLuoYTianJ.Multi-habitat based radiomics for the prediction of treatment response to concurrent chemotherapy and radiation therapy in locally advanced cervical cancer.Front Oncol2020;10:563
9.
VergoteIMagrinaJFZanagnoloVMagtibayPMButlerKGil-MorenoAFeijooB-DKimmigRCanisMBourdelN.The LACC trial and minimally invasive surgery in cervical cancer.J Min Inv Gynecol2020;27:462–3
10.
BoldriniLPirasAChiloiroGAutorinoRCelliniFCusumanoDFiondaBD’AvieroACampitelliMMarazziFBalducciMValentiniVGambacortaMA.Low Tesla magnetic resonance guided radiotherapy for locally advanced cervical cancer: first clinical experience.Tumori2020;106:497–505
11.
PereiraBBillaudMAlmeidaR.RNA-binding proteins in cancer: old players and new actors.Trends Cancer2017;3:506–28
12.
NyatiKKZamanMMSharmaPKishimotoT.Arid5a, an RNA-binding protein in immune regulation: RNA stability, inflammation, and autoimmunity.Trends Immunol2020;41:255–68
13.
ChouHLTianLKumamaruTHamadaSOkitaTW.Multifunctional RNA binding protein OsTudor-SN in storage protein mRNA transport and localization.Plant Physiol2017;175:1608–23
14.
HuXHarveySEZhengRLyuJGrzeskowiakCLPowellEPiwnica-WormsHScottKLChengC.The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing.Nat Commun2020;11:1–15
15.
ZhangYWangXZhangXWangJMaYZhangLCaoX.RNA-binding protein YTHDF3 suppresses interferon-dependent antiviral responses by promoting FOXO3 translation.Proc Natl Acad Sci2019; 116:976–81
16.
LukongKEChangKWKhandjianEWRichardS.RNA-binding proteins in human genetic disease.Trends Genet2008;24:416–25
17.
BomsztykKVan SeuningenISuzukiHDenisenkoOOstrowskiJ.Diverse molecular interactions of the hnRNP K protein.FEBS Lett1997;403:113–5
18.
MichelottiEFMichelottiGAAronsohnAILevensD.Heterogeneous nuclear ribonucleoprotein K is a transcription factor.Mol Cell Biol1996;16:2350–60
19.
GallardoMHornbakerMJZhangXHuPBueso-RamosCPostSM.Aberrant hnRNP K expression: all roads lead to cancer.Cell Cycle (Georgetown, Tex)2016;15:1552–7
LiuLLuoCLuoYChenLLiuYWangYHanJZhangYWeiNXieZ.MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.Oncogene2018;37:86–94
22.
PengWZLiuJXLiCFMaRJieJZ.hnRNPK promotes gastric tumorigenesis through regulating CD44E alternative splicing.Cancer Cell Int2019;19:335–11
23.
BarboroPRepaciERubagottiASalviSBoccardoSSpinaBTruiniMIntroiniCPuppoPFerrariNCarmignaniGBoccardoFBalbiC.Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer.Br J Cancer2009;100:1608–16
24.
BenelliRMonteghirfoSBalbiCBarboroPFerrariN.Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.Int J Cancer2009;124:2989–96
25.
CiarloMBenelliRBarbieriOMinghelliSBarboroPBalbiCFerrariN.Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells.Int J Cancer2012;131: 582–90
26.
CarpenterBMcKayMDundasSRLawrieLCTelferCMurrayGI.Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer.Br J Cancer2006;95:921–7
27.
OtoshiTTanakaTMorimotoKNakataniT.Cytoplasmic accumulation of heterogeneous nuclear ribonucleoprotein K strongly promotes tumor invasion in renal cell carcinoma cells.PLoS ONE2015;10: e0145769
28.
ChungICChenLCChungAKChaoMHuangHYHsuehCTsangNMChangKPLiangYLiHPChangYS.Matrix metalloproteinase 12 is induced by heterogeneous nuclear ribonucleoprotein K and promotes migration and invasion in nasopharyngeal carcinoma.BMC Cancer2014;14:348
29.
ZhangLFengJKongSWuMXiZZhangBFuWLaoYTanHXuH.Nujiangexathone A, a novel compound from Garcinia nujiangensis, suppresses cervical cancer growth by targeting hnRNPK.Cancer Lett2016;380:447–56
30.
LeeWJShinCHJiHJeongSDParkMSWonHHPandeyPRTsitsipatisDGorospeMKimHH.hnRNPK-regulated LINC00263 promotes malignant phenotypes through miR-147a/CAPN2.Cell Death Dis2021;12:290
31.
Song BaYWang MaFWei MaYChen BaDDeng BaG. ATP5A1 participates in transcriptional and posttranscriptional regulation of cancer-associated genes by modulating their expression and alternative splicing profiles in HeLa Cells.Technol Cancer Res Treat2021; 20:1–13
32.
JobkeBMilovanovicPAmlingMBusseB.Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.Bone2014;59:37–43
33.
PlumbJAMilroyRKayeS.Effects of the pH dependence of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.Cancer Res1989;49:4435–40
34.
YangXZhanPFengSJiHTianWWangMChengCSongB.SRSF6 regulates alternative splicing of genes involved in DNA damage response and DNA repair in HeLa cells.Oncol Rep2020;44:1851–62
35.
KimDPerteaGTrapnellCPimentelHKelleyRSalzbergSL.TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.Genome Biol2013;14:R36
36.
TrapnellCWilliamsBAPerteaGMortazaviAKwanGvan BarenMJSalzbergSLWoldBJPachterL.Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation.Nat Biotechnol2010;28:511–5
37.
RobinsonMDMcCarthyDJSmythGK.edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.Bioinformatics2010;26:139–40
38.
XiaHChenDWuQWuGZhouYZhangYZhangL.CELF1 preferentially binds to exon-intron boundary and regulates alternative splicing in HeLa cells.Biochim Biophys Acta Gene Regul Mech2017; 1860:911–21
39.
LiuJLiCWangJXuDWangHWangTLiLLiHNanPZhangJWangYHuangCChenDZhangYWenTZhanQMaFQianH.Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing.Nat Commun2020; 11:4455
40.
LiRZHouJWeiYLuoXYeYZhangY.hnRNPDL extensively regulates transcription and alternative splicing.Gene2019;687:125–34
41.
XieCMaoXHuangJDingYWuJDongSKongLGaoGLiCYWeiL.KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases.Nucleic Acids Res2011;39:W316–22
42.
AldinucciDColombattiA.The inflammatory chemokine CCL5 and cancer progression.Mediators Inflamm2014;2014:292376
43.
ForeroAOzarkarSLiHLeeCHHemannEANadjsombatiMSHendricksMRSoLGreenRRoyCN.Differential activation of the transcription factor IRF1 underlies the distinct immune responses elicited by type I and type III interferons.Immunity2019;51:451e6–64
44.
LiuJGuanXMaX.Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon γ-induced RANTES/CCl5 expression in macrophages.J Biol Chem2005;280:24347–55
45.
RomeoGFiorucciGChiantoreMVPercarioZAVannucchiSAffabrisE.IRF-1 as a negative regulator of cell proliferation.J Interferon Cytokine Res2002;22:39–47
46.
ChenXGuPXieRHanJLiuHWangBXieWXieWZhongGChenCXieSJiangNLinTHuangJ.Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer.J Cell Mol Med2017;21:1266–79
47.
RenyuanZReneéSNelsonMAAchyutBJiaqiS.Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.Int J Cancer2010;126: 395–404
48.
NagalakshmiUWangZWaernKShouCRahaDGersteinMSnyderM.The transcriptional landscape of the yeast genome defined by RNA sequencing.Science2008;320:1344–9
49.
ElinavENowarskiRThaissCAHuBJinCFlavellRA.Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms.Nat Rev Cancer2013;13:759–71
50.
SoriaGBen-BaruchA.The inflammatory chemokines CCL2 and CCL5 in breast cancer.Cancer Lett2008;267:271–85
51.
ZlotnikAYoshieONomiyamaH.The chemokine and chemokine receptor superfamilies and their molecular evolution.Genome Biol2006;7:243
52.
ChristophersonK2ndHromasR.Chemokine regulation of normal and pathologic immune responses.Stem Cells2001;19:388–96
53.
MackayCR.Chemokines: immunology’s high impact factors.Nat Immunol2001;2:95–101
54.
NiwaYAkamatsuHNiwaHSumiHOzakiYAbeA.Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer.Clin Cancer Res2001;7:285–9
55.
Leeman-NeillRJBhagatG.BCL6 as a therapeutic target for lymphoma.Expert Opin Ther Targets2018;22:143–52
56.
AngLZhengLWangJHuangJHuHGZouQZhaoYLiuQMZhaoMWuZS.Expression of and correlation between BCL6 and ZEB family members in patients with breast cancer.Exp Ther Med2017; 14:3985–92
57.
ZhuLFengHJinSTanMGaoSZhuangHHuZWangHSongZLinB.High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.Tumour Biol2017;39:1–12
58.
DebDRajaramSLarsenJEDospoyPDMarulloRLiLSAvilaKXueFCerchiettiLMinnaJDAltschulerSJWuLF.Combination therapy targeting BCL6 and phospho-STAT3 defeats intratumor heterogeneity in a subset of non-small cell lung cancers.Cancer Res2017;77:3070–81
59.
Tyson-CapperAGautreyH.Regulation of Mcl-1 alternative splicing by hnRNP F, H1 and K in breast cancer cells.RNA Biol2018;15: 1448–57
60.
BellutiSRigilloGImbrianoC.Transcription factors in cancer: when alternative splicing determines opposite cell fates.Cells2020;9:760
61.
Walch-RückheimBPahne-ZeppenfeldJFischbachJWickenhauserCHornLCTharunLBüttnerRMallmannPSternPKimY-J.STAT3/IRF1 pathway activation sensitizes cervical cancer cells to chemotherapeutic drugs.Cancer Res2016;76:3872–83
62.
LeeE-JJoMParkJZhangWLeeJ-H.Alternative splicing variants of IRF-1 lacking exons 7, 8, and 9 in cervical cancer.Biochem Biophys Res Commun2006;347:882–8
63.
LuZCasalino-MatsudaSMNairABuchbinderABudingerGRSSpornPHSGatesKL.A role for heat shock factor 1 in hypercapnia-induced inhibition of inflammatory cytokine expression.FASEB J2018; 32:3614–22
64.
IgarashiYOhnishiKIrieKMurakamiA.Possible contribution of zerumbone-induced proteo-stress to its anti-inflammatory functions via the activation of heat shock factor 1.PLoS ONE2016;11:e0161282
65.
KhanYMKirkhamPBarnesPJAdcockIM.Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells.PLoS ONE2014;9:e95051
66.
WangLZhengSZhangLXiaoHGanHChenHZhaiXLiangPZhaoJLiY.Histone deacetylation 10 alleviates inflammation after intracerebral hemorrhage via the PTPN22/NLRP3 pathway in rats.Neuroscience2020;432:247–59
67.
LiaoWSunJLiuWLiWJiaJOuFSuKZhengYZhangZSunY.HDAC10 upregulation contributes to interleukin 1beta-mediated inflammatory activation of synovium-derived mesenchymal stem cells in temporomandibular joint.J Cell Physiol2019;234:12646–62
68.
RatajOHaedicke Jarboui-JStubenrauchFIftnerT.Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: a potential new target in cervical cancer therapy.Int J Cancer2019;144:2330–8
69.
SongCZhuSWuCKangJ.Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression.J Biol Chem2013;288:28021–33
70.
DasSBhattacharyyaNP.Heat shock factor 1 regulates hsa-miR-432 expression in human cervical cancer cell line.Biochem Biophys Res Commun2014;453:461–6
71.
CollierBGoobar-LarssonLSokolowskiMSchwartzS.Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2.J Biol Chem1998;273:22648–56
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
